DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients

Information source: Hospital Universitari Vall d'Hebron Research Institute
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine Related Disorders

Intervention: Caffeine (Drug); Biperiden (Drug); Placebo (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: Hospital Universitari Vall d'Hebron Research Institute

Official(s) and/or principal investigator(s):
Miquel Casas, Prof., Principal Investigator, Affiliation: Hospital Universitari Vall d'Hebron Barcelona, Catalonia, Spain

Overall contact:
Miquel Casas, Prof., Phone: 0034 93 489 42 94, Email: mcasas@vhebron.net

Summary

The aim of this study is to assess the efficacy of caffeine compared to placebo in detoxifying cocaine dependent patients. Caffeine potentiation with biperiden will be also studied.

108 with cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t. i.d.)

plus biperidene (8 mg b. i.d.) or caffeine (300 - 1200 mg t. i.d.) with placebo or placebo

during 6 months.

Primary efficacy outcomes will be 1) patient comfort assessed with abstinence symptomatology, craving for cocaine and mental status during detoxifying period, 2) study retention and 3) cocaine use.

Brain dopamine system will be assessed thru IBZM-SPECT and the apomorphine test.

Clinical Details

Official title: Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: 1) comfort with cocaine detox defined as cocaine abstinence symptoms, cocaine craving, depressive symptoms and anxiety symptoms 2) study retention and 3) cocaine use.

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- diagnosis of intranasal cocaine dependence, according to DSM-IV-TR criteria

- age between 18 and 60 years

- current cocaine use, confirmed by a positive urine drug screen for cocaine the week

prior to admission.

- demonstrated capacity to grant informed consent and sign the pertinent informed

consent form.

- place of residence compatible with attendance at the centre.

- for women, willingness to use effective contraceptive measures during the study.

Exclusion Criteria:

- diagnosis of a severe medical disorder that could interfere with the study

- presence of an organic pathology for which methylxanthines or biperidene, iodine or

apomorphine administration is contraindicated

- serum liver transaminase levels 3 times higher than normal values

- pregnancy and breast-feeding

- neuroleptic medication treatment in the past 6 weeks

- current treatment, or anticipation that the patient may need to initiate treatment

during the study with drugs that may interact with study medication.

- current diagnosis of a major mental disorder.

- awareness of a situation that could prevent the patient's participation in the study

(e. g. serving a sentence)

- current participation in another research project.

Locations and Contacts

Miquel Casas, Prof., Phone: 0034 93 489 42 94, Email: mcasas@vhebron.net

Hospital Universitari Vall d'Hebron, Barcelona, Catalonia 08035, Spain; Recruiting
Miquel Casas, Prof, Phone: 0034 93 489 42 94, Email: mcasas@vhebron.net
Roncero Carlos, MD, Sub-Investigator
Xavier Castells, MD, Sub-Investigator
Mavi Trasobares, Sub-Investigator
Margarita Corominas, Sub-Investigator
Marta Ribas├ęs, Sub-Investigator
Sergi Valero, Sub-Investigator
Additional Information

Starting date: January 2005
Last updated: May 26, 2010

Page last updated: December 08, 2011

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014